IDH1 p.R132L
About
Gene context: IDH1
Biomarker Type: Somatic Variant
Present: True
Chromosome: 2
Start Position: 209113112
End Position: 209113112
Reference Allele: C
Alternate Allele: A
Cdna Change: c.385G>T
Protein Change: p.R132L
Variant Annotation: Missense
Exon: 4
Rsid: rs121913500
Hgvsg: 2:g.209113112C>A
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | IDH1 p.R132L | Acute Myeloid Leukemia | Ivosidenib | |
| EMA (1) FDA (1) | IDH1 p.R132L | Acute Myeloid Leukemia | Azacitidine, Ivosidenib | |
| FDA (1) | IDH1 p.R132L | Myelodysplastic Syndromes | Ivosidenib | |
| EMA (1) FDA (1) | IDH1 p.R132L | Cholangiocarcinoma | Ivosidenib | |
| FDA (1) | IDH1 p.R132L | Acute Myeloid Leukemia | Olutasidenib | |
| EMA (1) FDA (1) | IDH1 p.R132L | Astrocytoma | Vorasidenib | |
| EMA (1) FDA (1) | IDH1 p.R132L | Oligodendroglioma | Vorasidenib |